Get started
Author

Hrishikesh Krishna Srinagesh

Observed names: Hrishi Srinagesh, Hrishikesh K Srinagesh, Hrishikesh K. Srinagesh, Hrishikesh Srinagesh
ORCID: 0000-0001-9786-3010
Observed ORCID: 0000-0001-9786-3010
OpenAlex ID: A5084773736
Angiotensin II sustains brain inflammation in mice via TGF-β
2010 · Tobias V. Lanz, Zhaoqing Ding, et al. · Journal of Clinical Investigation · 198
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
2019 · Hrishikesh K. Srinagesh, Umut Özbek, et al. · Blood Advances · 111
PDF
CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study
2024 · Matthew J Frank, John H Baird, et al. · The Lancet · 72
PDF
Identification of Naturally Occurring Fatty Acids of the Myelin Sheath That Resolve Neuroinflammation
2012 · Peggy P. Ho, Jennifer L. Kanter, et al. · Science Translational Medicine · 67
CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results
2024 · Liora M. Schultz, Nikeshan Jeyakumar, et al. · Leukemia · 45
Biomarkers in acute graft- versus -host disease: new insights
2019 · Hrishikesh K. Srinagesh, John E. Levine, et al. · Therapeutic Advances in Hematology · 43
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
2020 · Stephanie C. Gergoudis, Zachariah DeFilipp, et al. · Blood Advances · 38
PDF
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
2020 · Mina D. Aziz, Jay Shah, et al. · Leukemia · 34
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia
2024 · Hrishikesh Srinagesh, Clayton Jackson, et al. · Blood · 27
MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application
2019 · Hrishikesh K. Srinagesh, James L.M. Ferrara · Best Practice & Research Clinical Haematology · 26
Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma
2024 · Sushma Bharadwaj, Eric Lau, et al. · Journal for ImmunoTherapy of Cancer · 20
PDF
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
2024 · Muna Qayed, Urvi Kapoor, et al. · Transplantation and Cellular Therapy · 14
CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy
2021 · Matthew J. Frank, John H. Baird, et al. · Blood · 8
Clinical and Cytokine Features of Immune Effector Cell–Associated Hemophagocytic Lymphohistiocytosis–Like Syndrome
2025 · Hrishikesh K. Srinagesh, Anne Marijn Kramer, et al. · Blood Cancer Discovery · 6
CD22 CAR T Cell-Related IEC-HS Is Associated with an IFN-γ Cytokine Signature
2023 · Hrishikesh Srinagesh, John H. Baird, et al. · Blood · 5
Effects of an Initial Anti-CD19 CAR T-cell Therapy on Subsequent Anti-CD22 CAR T-cell Manufacturing and Clinical Outcomes in Patients with Relapsed/Refractory LBCL
2025 · Yi-Jiun Su, Anne Marijn Kramer, et al. · Cancer Discovery · 4
Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
2026 · Hrishikesh K. Srinagesh, Vishal Gupta, et al. · Blood · 3
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world
2025 · Aaron Logan, Fevzi Yalniz, et al. · Blood · 3
PDF
Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis
2025 · Yannis Valtis, Karamjeet Sandhu, et al. · Blood · 3
PDF
CD22 CAR T Cell Therapy Induces Durable Remissions in Patients with Large B Cell Lymphoma Who Relapse after CD19 CAR T Cell Therapy
2023 · Matthew J. Frank, Bita Sahaf, et al. · Transplantation and Cellular Therapy · 3
Superior Chronic Graft-versus-Host Disease–Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation
2026 · Alfonso Molina, Quenton Rashawn Bubb, et al. · Transplantation and Cellular Therapy · 2
CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma with Superior Safety and Absence of Neurotoxicity
2025 · Hrishikesh K. Srinagesh, Anne Marijn Kramer, et al. · Transplantation and Cellular Therapy · 2
CD22-Directed CAR T Cell Single Cell Multiomic Features Associated with Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
2024 · Anne Marijn Kramer, Tara Murty, et al. · Blood · 2
CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma
2024 · Anne Marijn Kramer, Hrishikesh Srinagesh, et al. · Blood · 2
PDF
S230: Cd22 Car T Cell Therapy Is Safe and Effective in Patients With Large B Cell Lymphoma Who Have Relapsed After Cd19 Car T Cell Therapy.
2023 · Matthew J. Frank, John Baird, et al. · HemaSphere · 2
Works count: 103
Citation count: 746
H-index: 12
I10-index: 12
Year
Topic
Type